Sarepta Therapeutics (SRPT) Cash from Investing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$134.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 53.85% year-over-year to -$134.4 million in Q1 2026; TTM through Mar 2026 was $226.4 million, a 7.8% decrease from a year earlier, with the FY2025 full-year figure at $69.6 million, down 90.78% from the prior year.
• Cash from Investing Activities declined to -$134.4 million in Q1 2026 per SRPT's latest filing, from $96.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $764.1 million in Q4 2024 and bottomed at -$785.8 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $9.8 million (2022), against an average of -$30.7 million.
• Across the five-year window, Cash from Investing Activities sank 1201.37% in 2023 and surged 1651.49% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $9.8 million in 2022, then plunged by 756.98% to -$64.4 million in 2023, then soared by 1287.29% to $764.1 million in 2024, then sank by 87.41% to $96.2 million in 2025, then slumped by 239.69% to -$134.4 million in 2026.
• Per Business Quant, the three latest SRPT Cash from Investing Activities figures stand at -$134.4 million (Q1 2026), $96.2 million (Q4 2025), and $232.4 million (Q3 2025).